NewAmsterdam Pharma Co N.V.
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $22.5M
- Net income
- -$203.8M
- Total assets
- $769.3M
- Market cap
- $3.7B
- Operating margin
- -1002.9%
- Net margin
- -905.7%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $22.5M
- Operating expenses
- $248.2M
- Operating income
- -$225.7M
- Net income
- -$203.8M
- EPS (basic)
- $-1.72
- EPS (diluted)
- $-1.72
Balance sheet
- Total assets
- $769.3M
- Current assets
- $675.7M
- Total liabilities
- $85.9M
- Current liabilities
- $85.8M
- Shareholders’ equity
- $683.4M
Cash flow
- Operating cash flow
- -$147.8M
- Investing cash flow
- -$174.9M
- Financing cash flow
- $29.5M
- Net cash flow
- -$293.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.7B
- EPS (diluted)
- $-1.72
- Shares outstanding
- 119.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 23, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $203.8M in FY2025.
- Revenue grew 60% from FY2023 to FY2025.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NewAmsterdam Pharma Co N.V..
Write a review
News about NewAmsterdam Pharma Co N.V.
News & sentiment via Polygon.io
